Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2

Conditions

Carcinoma, Non-Small-Cell Lung 1364Lung Neoplasms 697Small Cell Lung Carcinoma 202Neoplasms 151Neoplasm Metastasis 130Breast Neoplasms 116Melanoma 99Colorectal Neoplasms 84Adenocarcinoma of Lung 84Ovarian Neoplasms 78Pancreatic Neoplasms 72Carcinoma, Renal Cell 69Head and Neck Neoplasms 66Mesothelioma 58Prostatic Neoplasms 53Urinary Bladder Neoplasms 52Mesothelioma, Malignant 51Stomach Neoplasms 47Triple Negative Breast Neoplasms 45Carcinoma 45Esophageal Neoplasms 43Brain Neoplasms 42Squamous Cell Carcinoma of Head and Neck 41Colonic Neoplasms 35Sarcoma 34Adenocarcinoma, Bronchiolo-Alveolar 33Recurrence 32Adenocarcinoma 31Uterine Cervical Neoplasms 30Parkinson Disease 4, Autosomal Dominant Lewy Body 29

Interventions

efatutazone 1Nivolumab 1Erlotinib Hydrochloride 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has results × Advanced Non-small Cell Lung Cancer (NSCLC) × Thoracic × Clear all
NCT02175017 2024-12-09

ONO-4538 Study in Patients With Advanced Non-Small Cell Lung Cancer

Ono Pharmaceutical Co., Ltd.

Phase 2 Completed
104 enrolled 21 charts
Thoracic

Advanced Non-small Cell Lung Cancer (NSCLC)

NCT01101334 2020-06-16

Study of Erlotinib With or Without Investigational Drug (CS-7017) in Subjects With Advanced Non-small Cell Lung Cancer

Daiichi Sankyo

Phase 2 Completed
90 enrolled 11 charts
Thoracic

Advanced Non-small Cell Lung Cancer (NSCLC)

Data powered by HemOnc (CC BY 4.0) Colophon âš¡